merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Lilly positioning vials as safer option than compounded drugs</answer>
<question_number>2</question_number>
<answer>By providing a telehealth platform that connects patients with providers and delivers authentic drugs directly to doors</answer>
<question_number>3</question_number>
<answer>Far less oversight, not controlled for safety, quality, and effectiveness</answer>
<question_number>4</question_number>
<answer>To regain customers using compounded tirzepatide by offering cheaper authentic alternative</answer>
<question_number>5</question_number>
<answer>Allows compounding pharmacies to make copycat versions until removed from list</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>Increased risk of muscle loss in older patients leading to fractures or frailty</answer>
<question_number>8</question_number>
<answer>By highlighting compounded drugs' risks and positioning vials as safer</answer>
<question_number>9</question_number>
<answer>FDA shortage list</answer>
<question_number>10</question_number>
<answer>Lower pricing</answer>